US EditionSERA PROGNOSTICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS
Vuzix cut operating expenses by 22% year-over-year and secured $5 million from Quanta, while gaining volume orders from a major retailer and a defense contract.
- On November 13, 2025, Vuzix Corporation , Rochester, New York, reported third-quarter results for the quarter ended September 30, 2025, with a $7.4 million net loss and $1.2 million in revenue.
- Revenue weakness came from a 9% decline in M400 smart glasses sales and a 33% drop in engineering services, while a $0.2 million gross loss increase and 22% year-over-year operating expenses cut pressured margins.
- Meeting milestone criteria, Vuzix received $5 million from Quanta Computer, bringing total investment to $20 million, secured initial purchase orders from a leading global online retailer, and appointed Dr. Chris Parkinson, President, Vuzix Enterprise Solutions.
- As of September 30, 2025, Vuzix held cash and cash equivalents $22.6 million and working capital $24.3 million, with net cash flows used in operating activities $5.0 million in Q3 2025.
- For Q4 2025, Vuzix expects robust growth driven by in‑flight OEM programs and a high six‑figure smart‑glasses backlog while showcasing co‑developed concepts with OEM partners at CES 2026 and leveraging its Quanta Computer partnership.
69 Articles
69 Articles
MDA SPACE REPORTS THIRD QUARTER 2025 RESULTS
Q3 2025 HighlightsBacklog of $4.4 billion at quarter-end, provides revenue visibility for 2025 and beyondRevenues of $409.8 million, up 45% YoYAdjusted EBITDA 1 of $82.8 million, up 49% YoY, and adjusted EBITDA margin 1 of 20.2%Adjusted net income 1 of…
Atlas Energy Reports Third Quarter 2025 Financial Results
CALGARY, Alberta, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Atlas Energy Corp. (“Atlas” or the “Company”) (TSXV: ATLE), a TSXV Sandbox issuer, is pleased to announce its unaudited consolidated interim financial statements and related management’s discussion and analysis (“MD&A”) for the…
Aptose Reports Third Quarter 2025 Results
Tuspetinib Continues to Demonstrate Excellent Safety and Complete Responses in the TUSCANY Clinical Trial of Tuspetinib in AML Triple Drug Frontline Therapy at Increased Dose LevelsPatients are Now Being Treated at 160 mg Dose of Tuspetinib
Coverage Details
Bias Distribution
- 59% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
